Cargando…
Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levo...
Autores principales: | Du, Xiwen, Han, Yi, Jian, Yifei, Chen, Liping, Xuan, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/ https://www.ncbi.nlm.nih.gov/pubmed/34584913 http://dx.doi.org/10.1016/j.dib.2021.107352 |
Ejemplares similares
-
A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007) -
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020) -
Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002) -
Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
por: Kuzman, Ilija, et al.
Publicado: (2014) -
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2017)